Taking GLP-1s While On BP Meds May Up Your Risk Of Dizzy Spells, Fainting
MONDAY, June 15, 2026 — Researchers are flagging a potential safety concern tied to GLP-1 medications and blood pressure.
A new Northwestern Medicine study tracked more than 42,000 adults who started semaglutide, tirzepatide or liraglutide…
New GLP-1 diabetes pill delivers major weight loss and blood sugar control
A new oral GLP-1 medication helped people with type 2 diabetes dramatically improve blood sugar control and lose weight in a major clinical trial. The results suggest that highly effective diabetes treatments may soon become available in a much more convenient pill form.
Semaglutide linked to lower bone fracture risk
Tuesday, June 16 – In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared with other anti-obesity medications, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.
More than half of those who stop GLP-1s restart within a year, study finds
Tuesday, June 16 – People prescribed GLP-1 medications are more likely to start and stop than most people assume, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.
People taking GLP-1 weight loss drugs like Ozempic started moving less
Tuesday, June 16 – People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long-term health.
Study finds exercise decreases among people taking GLP-1 medication
Sunday, June 14 – Adults with obesity who lost weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.
GLP-1 and SGLT2 Users Face Different Risk for Diabetic Foot Complication
Sunday, June 14 – (MedPage Today) — CHICAGO — Use of GLP-1 receptor agonists was tied to significantly lower risks of major diabetic foot complications compared with SGLT2 inhibitors in adults with type 2 diabetes, a large, real-world analysis indicated.
Compared…
Could a once-a-day pill replace weight loss injections? Phase II oral GLP-1 drug trial shows promising results
Sunday, June 14 – For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news. Researchers are testing a new oral, small-molecule GLP-1 receptor agonist called Elecoglipron, which could offer the weight-loss benefits of GLP-1 therapy without injections.
GLP-1s tied to elevated risk of fainting, dizziness
Sunday, June 14 – Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications. After starting GLP-1s, these patients experienced higher rates of dizziness, fainting and other events related to low blood pressure, also known as hypotension.
Survodutide weight-loss drug may reduce harmful fat while preserving muscle
Saturday, June 18 – Survodutide weight-loss drug may reduce harmful fat while preserving muscle.